Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

New trial results from the international RAPID Trial show that administering a full dose of a standard blood thinner early to moderately ill hospitalized patients with COVID-19 could halt the thrombo-inflammation process and reduce the risk of severe disease and death. How to anticoagulate COVID patients. How to prevent thrombus in COVID patients.
Feature | Coronavirus (COVID-19)

July 15, 2021 — COVID-19 is marked by heightened inflammation and abnormal clotting in the blood vessels, particularly ...

Home July 15, 2021
Home
Videos | Structural Heart

Doctor Andreas Ruck, interventional cardiologist and head of the mitral/tricuspid program, Karolinska University ...

Home July 14, 2021
Home
News | Cardiovascular Ultrasound

July 13, 2021 — Researchers at Johns Hopkins Medicine have shown that speckle-tracking strain echocardiograms may ...

Home July 14, 2021
Home
The Xeltis synthetic polymer restorative pulmonary valve is implanted surgically and acts as a scaffold for the patient's own cells to proliferate. The valve and conduit then bioresorbs over time, leaving behind a new valve made from the patient's own cells. The hope is this will reduce or eliminate the need for numerous repeat surgeries as a pediatric patient grows.
Feature | Heart Valve Technology

July 8, 2021 – Xeltis announced it started the first pivotal trial for a synthetic polymer restorative pulmonary valve ...

Home July 08, 2021
Home
Videos | Artificial Intelligence

Federico Asch, M.D., FASE, director of cardiovascular core labs, cardiovascular imaging, MedStar Health Research ...

Home July 01, 2021
Home
News | Womens Cardiovascular Health

June 29, 2021 – Three research studies presented at the American Society of Echocardiography (ASE) 2021 virtual meeting ...

Home June 29, 2021
Home
News | Congenital Heart

June 29, 2021 – Echocardiography with ultrasound enhancing agents (UEAs) has proven to be a valuable imaging procedure ...

Home June 29, 2021
Home
News | Coronavirus (COVID-19)

June 28, 2021 - A recent analysis found that children and adolescents with multisystem inflammatory syndrome in children ...

Home June 28, 2021
Home
A small number of patients develop myocarditis after receiving the messenger RNA (mRNA) COVID-19 vaccines from Pfizer and Moderna. This recently raised concerns after numbers for this adverse reaction jumped in April and May, prompting review this week by the Centers for Disease Control and Prevention (CDC) Advisory Committee on the Immunization Practices (ACIP).
Feature | Coronavirus (COVID-19) | By Dave Fornell, Editor

A small number of patients develop inflammation leading to myocarditis after receiving the messenger RNA (mRNA) COVID-19 ...

Home June 24, 2021
Home
News | Cardiovascular Clinical Studies

June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) regis ...

Home June 24, 2021
Home
Small Number of Patients Have Myocarditis-like Illness After COVID-19 Vaccination. Photo by Dave Fornell
Feature | Coronavirus (COVID-19)

June 23, 2021 — Findings from a small study detailing the treatment of myocarditis-like symptoms in seven people after ...

Home June 23, 2021
Home
News | FFR Technologies

June 22, 2021 – Philips Healthcare announced the official start of the DEFINE GPS study, with the first patient being ...

Home June 22, 2021
Home
Blog | Structural Heart

It is brutal and very expensive to bring a new transcatheter valve to market. Boston Scientific invested vast amounts of ...

Home June 08, 2021
Home
Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no differences is therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI.
Feature | ACC | By Dave Fornell, Editor

Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021 Americ ...

Home June 08, 2021
Home
News | Peripheral Artery Disease (PAD)

June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery ...

Home June 07, 2021
Home
Subscribe Now